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Highlights 34 
PBK models have helped to facilitate quantitative in vitro to in vivo extrapolation 35 
PBK modelling has the potential to play a significant role in reducing animal testing 36 
It is critical to assess the validity of PBK models built using non-animal data 37 
A framework is needed for communicating characteristics and results of PBK modelling 38 
 39 
 40 
 41 
  42 
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Abstract 43 
The fields of toxicology and chemical risk assessment seek to reduce, and eventually replace, the use of animals 44 
for the prediction of toxicity in humans. In this context, physiologically based kinetic (PBK) modelling based on 45 
in vitro and in silico kinetic data  has the potential to a play significant role in reducing animal testing, by providing 46 
a methodology capable of incorporating in vitro human data to facilitate the development of in vitro to in vivo 47 
extrapolation of hazard information. In the present article, we discuss the challenges in: 1) applying PBK 48 
modelling to support regulatory decision making under the toxicology and risk-assessment paradigm shift 49 
towards animal replacement; 2) constructing PBK models without in vivo animal kinetic data, while relying solely 50 
on in vitro or in silico methods for model parameterization; and 3) assessing the validity and credibility of PBK 51 
models built largely using non-animal data. The strengths, uncertainties, and limitations of PBK models 52 
developed using in vitro or in silico data are discussed in an effort to establish a higher degree of confidence in 53 
the application of such models in a regulatory context. The article summarises the outcome of an expert 54 
workshop hosted by the European Commission Joint Research Centre (EC-JRC) - European Union Reference 55 
Laboratory for Alternatives to Animal Testing (EURL ECVAMͿ, oŶ ͞PhǇsiologiĐallǇ-Based Kinetic modelling in risk 56 
assessment – reaching a whole new level in regulatory decision-ŵakiŶg͟ held iŶ Ispƌa, ItalǇ, iŶ Noǀeŵďeƌ ϮϬϭϲ, 57 
along with results from an international survey conducted in 2017 and recently reported activities occurring 58 
within the PBK modelling field. The discussions presented herein highlight the potential applications of next 59 
generation (NG)-PBK modelling, based on new data streams.  60 
Keywords: Physiologically Based kinetic models; PBPK; PBTK;  Toxicokinetics; In vitro; In silico.-   61 
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Introduction 62 
Modelling and simulation based approaches are gradually gaining interest as critical tools for safety and risk 63 
assessment of a variety of compounds including drugs, chemicals, consumer products, and food ingredients. 64 
These modelling approaches are recognised for the crucial role they play in, for example, predicting the 65 
biokinetics of drugs and chemicals in the organism without the need to conduct in vivo experiments. For more 66 
than 40 years, physiologically-based kinetic (PBK) models have been used to simulate biokinetics (Andersen and 67 
Krishnan, 2010; Mumtaz et al., 2012; Krishnan and Peyret, 2009; Bois et al., 2017). In PBK models, the body is 68 
represented as a series of interconnected compartments linked via blood flow, as depicted in the schematic 69 
below (Figure 1a), to simulate concentration-time curves in target organs or their surrogates, such as in blood 70 
(Figure 1b). PBK models use differential equations to describe the absorption, distribution, metabolism, and 71 
elimination (ADME) processes that govern the fate and transport of the chemical among these interconnected 72 
compartments. Proper use of PBK models helps to reduce uncertainties and to identify data gaps inherent in 73 
hazard characterisation approaches that rely upon default extrapolation factors (e.g., a multiplication factor of 74 
10 for inter-species extrapolation) to derive health-based guidance values from animal toxicity studies. PBK 75 
models provide a sound scientific basis to extrapolate across species, routes of exposure, and exposure 76 
scenarios, based on physiology and (physico-)chemical properties (Loizou et al., 2008; Bessems et al., 2014). As 77 
PBK models can be developed for specific individuals within the human population, they provide a means for 78 
quantifying inter-individual differences in kinetics, allowing for the determination of extrapolation factors across 79 
age groups or across populations of varying susceptibilities. With this information, safe chemical intake levels 80 
can be derived for individuals and populations. Most recently, PBK models have helped to facilitate quantitative 81 
in vitro to in vivo extrapolation (QIVIVE) approaches (Yoon et al., 2012, 2014, 2015; Wetmore et al., 2015; Louisse 82 
et al., 2017), enabling the use of in vitro toxicity data for the setting of safe intake levels. QIVIVE is an essential 83 
process in linking an in vitro measured biological (adverse) readout to a potential in vivo outcome (Groothuis et 84 
al., 2015). QIVIVE provides a means of considering exposure and dosimetry, and enables the use of in vitro 85 
toxicity data for risk-based assessments beyond hazard-based assessments (Bell et al., 2018). Once an in vitro 86 
concentration-response has been generated, the benchmark dose approach can be applied to the predicted 87 
dose – response data, to obtain an in vitro-based point of departure (PoD) or Reference Point (RfP) (Louisse et 88 
al., 2015; 2017). 89 
Nomenclature 90 
͞PhǇsiologiĐallǇ ďased phaƌŵaĐokiŶetiĐ͟ ;PBPKͿ model is the most widely used term and was developed by the 91 
pharmaceutical field to simulate the kinetics of drugs. Despite the popular use of the term, ͞PBPK͟ is Ŷot eŶtiƌelǇ 92 
correct in the context of general chemical risk assessment. Another term preferred in the European Union (EU) 93 
and related to ĐheŵiĐal ƌisk assessŵeŶt is ͞PBTK͟, where TK is the abbreviation for ͞toxicokinetics͟. Hoǁeǀeƌ, 94 
this term is not entirely appropriate either (Clewell et al., 2008). Rather, a more general nomenclature, such as 95 
physiologically based biokinetic (PBBK) or the aforementioned PBK, might be seen as more appropriate. 96 
Regardless of the terminology used, PBK, PBPK, PBBK and PBTK can all be considered synonyms, and so 97 
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throughout this document we will consistently use the more general terms of PBK model or PBK modelling. It is 98 
noted that the ever-increasing advancements in in vitro and in silico methodologies in the field of toxicology can 99 
be used in combination with PBK models to support regulatory decisions on the use of chemical substances.  In 100 
the present manuscript the term next generation PBK (NG-PBK) model will be used to name these models. This 101 
term, NG-PBK, refers to PBK models that are developed without the provision of newly produced (i.e., without 102 
animal sacrifice) animal TK data for parametrisation and validation of those models, but rather through 103 
supporting in vitro, in silico, -omics, micro-scale applications. NG-PBK  models representing the human body 104 
should be parameterized and validated using in vitro, in silico, -omics data, micro-scale systems, and human in 105 
vivo data, when available. This stands also for PBK models built to represent animals (e.g. livestock, fish, bees), 106 
which should be  parameterized and validated using in vitro, in silico, -omics, micro-scale systems and historical 107 
or (bio)-monitoring animal data of the species of interest,  to avoid the need for animal sacrifice. 108 
Milestones in the history of PBK modelling 109 
The principles behind PBK modelling were first reported in 1937 by Teorell, in a publication eŶtitled ͞KiŶetiĐs of 110 
distƌiďutioŶ of suďstaŶĐes adŵiŶisteƌed to the ďodǇ͟ ;Teoƌell, ϭϵϯϳͿ. Although Teoƌell͛s ǁoƌk ǁas the fiƌst 111 
attempt to describe the body as a series of equations, the complexity of the mathematics, lack of data, and lack 112 
of computing power rendered his concepts incomplete until the 1960s. Between the 1960s and 1970s, several 113 
PBK models were developed for pharmaceutical drugs to target cancers  (Bischoff and Dedrick 1968; Bischoff et 114 
al. 1970). These publications paved the way for more than 2000 articles written on the topic of PB(P/T)K 115 
modelling within the last forty years (Figure 2a). Over the past decade, there has been an increase in the 116 
development of PBK models for use in a variety of scientific fields, such as pharmacology, forensic sciences, and 117 
chemical risk assessment (Figure 2b), although such an increase was not seen for toxicology and veterinary 118 
medicine. Many risk assessors remain reluctant to apply these models within their work (Paini et al. 2017b, Punt 119 
et al., 2017, 2018), as PBK models are not often included in current hazard characterization and risk assessment 120 
protocols. In addition, some regulatory agencies may often have limited experience in using PBK models, and 121 
the complexity associated with the evaluation of model performance has also contributed to this reluctance. 122 
Over the past 20 years, several workshops have been held to promote the applicability of PBK models in the 123 
academic, industrial, and regulatory sectors. For example, a 1995 European Centre for the Validation of 124 
Alternative Methods (ECVAM) workshop discussing the use of biokinetic and in vitro methods resulted in 15 125 
recommendations that were submitted to support and guide future work in the PBK modelling field (Blaauboer 126 
et al., 1996). This workshop was followed by many others to better define the potential role of PBK modelling in 127 
science and risk assessment following a Three R (replacement, reduction and refinement) strategy (Bouvier 128 
d͛Yǀoiƌe et al., ϮϬϬϳͿ. In the same year, a workshop to address uncertainty and variability analysis in PBK 129 
modeling was held by Barton et al. (2007). Loizou et al. (2008) reported the need for clear descriptions of good 130 
modelling practices (GMP) for: 1) model development; 2) model characterisation; 3) model documentation; and 131 
4) model evaluation. A subsequent thematic workshop aimed to critically appraise PBK modelling software 132 
platforms and to provide a more detailed state-of-the-art overview of non-animal based PBK parameterisation 133 
tools (Bessems et al., 2014). A CEN (European Committee for Standardization) workshop in 2014 strived for 134 
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agreement upon the minimum requirements for the amount and type of information to be provided for 135 
exposure models, such as PBK models, along with documentation and guidelines for the structure and reporting 136 
of such information. The resulting CEN workshop agreement (CWA) was expected to provide a more rigorous 137 
means of describing exposure models and to aid users in better understanding them (Ciffroy et al., 2016a; 138 
Altenphol et al., 2018). The following year, a workshop assessed the state of knowledge in the application of PBK 139 
models in regulatory decision-making, in addition to sharing and discussing best practices in the use of PBK 140 
modelling to inform dose selection in specific patient populations (Wagner et al., 2015). In 2017, a workshop 141 
organized by the National Centre for the Replacement, Refinement, and Reduction of Animals in Research 142 
(NC3Rs) encouraged experts in exposure science to consider the role of PBK models in the extrapolation of 143 
external exposure data to internal concentrations to promote the application  of non-animal data in efficacy and 144 
safety testing  (Burden et al., 2017; https://www.nc3rs.org.uk/applying-exposure-science-increase-utility-non-145 
animal-data-efficacy-and-safety-testing Ϳ. A LoƌeŶtz CeŶteƌ ǁoƌkshop eŶtitled ͞NoŶ-animal Methods for 146 
Toxicokinetics: MeetiŶg Neǁ Paƌadigŵs iŶ ToǆiĐologǇ͟ ǁas held at the end of 2017 and emphasized the role of 147 
PBK models (https://www.lorentzcenter.nl/lc/web/2017/943/info.php3?wsid=943&venue=Oort; 148 
https://www.lorentzcenter.nl/lc/web/2017/943/report.pdf). The first European Partnership for Alternative 149 
Approaches to Animal Testing (EPAA) partners͛ forum, held at the end of 2017, aimed to provide an overview 150 
on toxicokinetics and read-across with insight into the role of PBK models (Laroche et al., 2018).   151 
 152 
Framing the problem 153 
The EURL ECVAM Strategy on Toxicokinetics1, as published in 2015, outlines opportunities for generating and 154 
making better use of TK data. The central feature of the strategy focuses on the use of PBK modelling to integrate 155 
data from in vitro and in silico methods for prediction of human whole-body biokinetic behavior, and enables 156 
QIVIVE to obtain safety guidance values expressed as external doses (Bell et al., 2018). In the past, in vivo 157 
tissue/blood concentration-time data were a prerequisite for calibrating and evaluating the predictive capability 158 
of a PBK model (Bessems, et al., 2014). The common practice was to start with an animal PBK model, calibrating 159 
it with animal in vivo data, and then re-parameterizing it based on in vitro biotransformation measurements or 160 
allometric scaling to develop a human PBK model. As the field of risk assessment evolves towards the goal of 161 
reducing, and eventually replacing, the use of animals for predicting human toxicity, PBK model development 162 
has seen a shift towards increased use of non-animal data for parameterization, along with increased use of the 163 
models for IVIVE. Efforts in this area should be directed towards developing standards that will increase the 164 
acceptance of in vitro methods for characterizing human-relevant ADME properties. To enhance the acceptance 165 
of PBK models at an international level, good modelling practice is required to guide the use of the in vitro and 166 
in silico methodologies in developing PBK models. As the first step, to initiate a dialogue on such a topic, the 167 
EuƌopeaŶ CoŵŵissioŶ͛s Joint Research Centre (JRC), EURL ECVAM, hosted a ǁoƌkshop oŶ ͞PhǇsiologiĐallǇ-Based 168 
Kinetic modelling in risk assessment – reaching a whole new level in regulatory decision-ŵakiŶg͟ ;Ispƌa, ItalǇ, 169 
November 16–17, 2016). The workshop participants discussed challenges in: 1) applying NG-PBK modelling to 170 
                                                          
1 https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/eurl-ecvam-strategy  
achieving-3rs-impact-assessment-toxicokinetics-and-systemic-toxicity?search 
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support regulatory decision making; 2) constructing PBK models for safety assessment without animal in vivo 171 
data, relying solely on in vitro or in silico methods; and 3 assessing the validity of PBK models that rely only upon 172 
non-animal data. A portion of this current article summarizes the outcome of the workshop; detailed 173 
information on the workshop outcomes can be found in the workshop report (Paini et al., 2017a).  174 
In addition to the EURL ECVAM workshop, an international survey was conducted in 2017 to understand the 175 
applications of PBK modelling in the broader scientific and regulatory communities. An aggregate summary, 176 
including analysis of the results, has been published (Paini et al., 2017b), while results presented per individual 177 
country are available online at http://apps.klimeto.com/pbk/. The survey provides insight into the current state 178 
of knowledge throughout the PBK modelling and user community, as well as a cursory volunteer contact list of 179 
modellers available for peer reviewing models. The main findings of the survey showed that though continuous 180 
expansion of the modelling community has allowed PBK models to gain ground for use in various scientific and 181 
regulatory risk assessment applications, this remains a slow process, due to a lack of guidance, data, and 182 
expertise, which continue to limit widespread acceptance of those models in such applications (Paini et al., 183 
2017b). Here, we  also discuss  recently reported activities in the field, (subsequent to  the  2016  EURL ECVAM  184 
workshop)  that demonstrate both ongoing developments in the field and the continued hesitancy within public 185 
health agencies to apply PBK modelling in their decisions. In addition, we will introduce as a new challenge the 186 
integration of NG-PBK modelling with toxicodynamic endpoints, as this will be essential for implementation of 187 
NG-PBK models. 188 
 189 
Salient Features: Applying NG-PBK modelling to support regulatory decision making 190 
As concluded from the 2017 survey (Paini 2017b), training, guidance, and dialogue are three main factors that 191 
will facilitate the successful acceptance of NG-PBK modelling in regulatory decision-making. 192 
1. Dialogue and Communication 193 
While training and guidance are both essential, their maximum benefits cannot be achieved without frequent 194 
dialogue between regulators, modellers, and model proponents (chemical registrants). Such frequent dialogue 195 
not only allows the proposers to better understand the needs of the regulators, but also allows the regulators 196 
to provide modellers with feedback throughout the development, evaluation, and application processes. For 197 
example, risk assessors present at the 2016 EURL ECVAM workshop indicated that they prefer to use the simplest 198 
model possible, as finding sufficient input data is rather challenging, but would be willing to use more complex 199 
models if necessity dictates and sufficient input data are available. Thus, dialogue can help regulators to convey 200 
their needs for specific training and for model features, and help proponents to understand the criteria 201 
necessary for regulatory acceptance. Conversely, the regulators can learn what is technically or scientifically 202 
feasible and what is not. As such dialogue may prove to be time-consuming, establishing a harmonized template 203 
for model construction and evaluation would facilitate the process. The template should be flexible enough for 204 
any regulatory agency or country to use, and would ideally incorporate an agreed-upon ontology . To efficiently 205 
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develop a PBK model to support regulatory risk assessment, modellers and end users (proponents and 206 
regulators) need to clearly define their goals of model use and related model requirements at an early stage. For 207 
example, if a read-across approach is likely to be applied by the end users, biokinetic data for a pre-determined 208 
set of relevant chemicals (target and source chemicals) will constitute important supporting material and should 209 
be included in the submission package. In situations where safety assessment is conducted for a new chemical 210 
on the market, the following criteria may be used to facilitate regulatory acceptance of a PBK model for this 211 
substance: 1) the model should be transparent, with a usable code; 2) model uncertainty should consider 212 
biological plausibility, and be clearly described and quantified when possible; 3) uncertainty in exposure 213 
scenarios should be characterised, because this uncertainty will propagate to PBK model results; 4) user-friendly 214 
platforms should be used where possible; 5) the model should be fit-for-purpose with no unnecessary additional 215 
complexity, and with all required parameters measurable; and 6) the model should consider sufficient coverage 216 
of chemical space, to allow for read-across approaches if desired. In cases where the model performance needs 217 
to be evaluated using human in vivo data, regulators may consider using data that are generated from human 218 
trials, such as micro-dosing. It should be emphasized that clinical studies would only be conducted once the 219 
safety of the chemical has been established and the clinical investigation represents de minimis risk to the 220 
subjects.   221 
 222 
2. Training  223 
Within the current climate of desire to reduce, refine, and replace animal testing through ongoing scientific and 224 
technological advancements, it would be beneficial to risk assessors / managers and other workers in safety 225 
assessment to be kept abreast of the development of NG-PBK models . In order to achieve this goal, information 226 
on  a number of novel emerging technologies, in addition to PBK modelling, should be made more accessible. 227 
These include -omics, organ- on-a -chip, high-throughput screening methods, read-across, Adverse Outcome 228 
Pathways (AOPs), and IVIVE. Additionally, it would be helpful if guidance were available indicating  how these 229 
different approaches are integrated in support of chemical safety assessment. On the other hand, it is not 230 
necessary for risk assessors/managers, etc.  to have detailed knowledge related to all the diverse aspects of PBK 231 
modelling; rather, it may be sufficient to provide tailored training that focuses only on the specific needs of each 232 
regulatory sector and, where applicable, cross-sector needs. For example, some risk assessors may need or wish 233 
to run a model, and so they would require knowledge of the relevant software and expertise to review and run 234 
model codes. Other risk assessors may rely on a model peer review system to check the implementation and 235 
reliability of new model codes, and in this case, may only require sufficient knowledge to allow for interpretation 236 
of the data and to enable modelling predictions to be put in context. One option is for risk assessors to  assemble 237 
technical committees that consist of members possessing a range of expertise, to review the model code and 238 
interpret model results. The training content/format should also be tailored to achieve maximum effectiveness 239 
in understanding the application of models. In addition to the traditional classroom setting, training formats 240 
could include webinars, ad hoc short courses, and more refined or specialised graduate-level courses. Further, 241 
online training could potentially generate a larger audience that would also allow the modelling and user 242 
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community to continue to expand. Finally, since risk assessors generally place higher confidence in in vivo data, 243 
there is a need to make courses on alternative in vitro and in silico methods more accessible, to provide a path 244 
forward to acceptance of these NG-PBK model applications in regulatory decision making.  245 
3. Guidance 246 
While training is essential, establishing guidance and GMP on PBK model applications intended for regulatory 247 
purposes is also critical (Loizou et al., 2008). The GMP should include clear documentation on how to report a 248 
ŵodel͛s sĐope aŶd puƌposes, details of ŵodel deǀelopŵeŶt aŶd eǀaluatioŶ, iŶteƌpƌetatioŶ of ƌesults, aŶd 249 
applications of the model in risk assessment (Loizou et al., 2008). It is recommended that the individual(s) or 250 
community network(s) responsible for each specific step in the development, evaluation, and application 251 
process be clearly identified, to increase transparency and allow end users to identify where targeted training 252 
may be required, if necessary, for a specific topic. The context in which the model is to be used, and thus the 253 
scope of the model development or amendment(s), should be clearly documented. This is especially important 254 
to avoid misuse of a reliable model, such as when results of the simulations are applied for the wrong purpose 255 
or when the model is applied outside of its applicability domain.  256 
The WHO-IPCS published, in 2010, a guidance document on the characterisation and application of PBK models 257 
in risk assessment (WHO, 2010). Nevertheless, no comprehensive guidance documentation is currently available 258 
for reporting and evaluating NG-PBK models without use of animal in vivo TK data, or for interpreting and 259 
applying outputs from these models for human safety assessment. Recently, several efforts have been made to 260 
produce such documentation. For example, the Scientific Committee for Consumer Safety (SCCS) considers all 261 
available scientific data in their safety evaluation of cosmetic substances, including data generated from PBK 262 
modelling. In the most recent Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety 263 
Evaluation (SCCS/1564/15)2, the SCCS defines the conditions for the use of PBK models submitted for risk 264 
assessment purposes. PBK modelling has already been accepted as a tool for risk assessment or for use as 265 
supporting information in some of the chemical-specific dossiers evaluated by the SCCS, EFSA, and US-EPA. The 266 
SCCS document could act as a starting point or as a template for a new general guidance document. Additionally, 267 
the new reporting guidelines from the US Food and Drug Administration (FDA) and European Medicine Agency 268 
(EMA) (US FDA, 2018; EMA, 2016), on harmonization of reporting and on qualification of PBK modelling and 269 
simulation, can also apply to NG-PBK models. To extend this concept, a working group at the Organisation for 270 
Economic Co-operation and Development (OECD), comprised of more than 45 scientists from different areas of 271 
scientific expertise, are drafting a guidance document for characterizing, validating, and reporting uncertainties 272 
in NG-PBK model applications. 273 
 274 
Salient Features: Constructing PBK models for safety assessment without animal in vivo data  275 
                                                          
2 http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_190.pdf 
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PBK models are built using three sets of parameters: i) physiological and anatomical parameters, with  276 
representative reference parameters taken from the species under study (animal or human); ii) biokinetic / 277 
ADME properties, which can be gathered using in vitro methods or by fitting the model to an in vivo data set; 278 
and iii) physico-chemical parameters, which are experimentally derived or obtained using in silico approaches 279 
such as quantitative activity relationship (QSAR) models (Rietjens et al., 2011). For GMP, the PBK model 280 
construction should consider the compound exposure situation/dosing strategy to be simulated (problem 281 
formulation). The exposure descriptions should include route of administration, timeframe of the simulation 282 
(i.e. exposure duration), and exposure frequency. In the cases of complex models that include inter-individual 283 
variability among some physiological values, the number of individuals that should be incorporated into the 284 
simulation for sufficient statistical power analysis should also be considered.   285 
In the case of NG-PBK models, assuming there is no possibility of generating in vivo animal data for the model 286 
calibration, there are two key pre-requisites to build the model: 287 
 Availability of in vitro and in silico alternatives to generate ADME properties (including prediction of 288 
metabolism) of sufficient quality 289  Availability and accessibility of modelling platforms. 290 
 291 
1. Availability of in vitro and in silico data for ADME properties 292 
Without in vivo data, the values of parameters in a PBK model will need to be derived from the results of in silico 293 
or in vitro experiments. Clearly, the accuracy of PBK models will be heavily reliant upon the quality of the model 294 
parameters, which often are not only tissue dependent but also chemical dependent. 295 
As it is useful to determine the minimum requirements for PBK models (with respect to data-poor and data-rich 296 
chemicals), a decision tree indicating requirements for different scenarios is presented here  (Figure 3). The most 297 
minimalistic model type, one-compartment models, parameterised with only protein binding and clearance 298 
data, have been developed and used to support chemical screening and prioritization (Rotroff et al., 2010; 299 
Wetmore et al., 2012, 2013, 2014; Tonnelier et al., 2012; Yoon et al., 2014; Wambaugh et al. 2015). Depending 300 
on the exposure route, a compartment representing the skin, intestine, or lung may need to be included in a 301 
model. If a compound is highly lipophilic, a fat compartment is required, and it may also be necessary for the 302 
model to describe uptake into the lymphatic system. Finally, depending on the hazard data available, additional 303 
compartments and biological processes may need to be added to the PBK model. Throughout development of 304 
the ŵodel, as ŵoƌe speĐifiĐ iŶfoƌŵatioŶ is oďtaiŶed oŶ the ĐheŵiĐal͛s pƌopeƌties aŶd ŵode of aĐtioŶ ;MoAͿ, 305 
confidence is increased in the applicability of the models. A good strategy would be to begin with a generic 306 
model structure, then move to more specific models once knowledge is gained that indicates a unique biokinetic 307 
behavior of the compound in question. In using a simple model, it is possible that a key kinetic pathway specific 308 
to a given target chemical will not be taken into consideration. To address this issue, a database of all known 309 
ADME/TK processes, such as cell uptake (capturing the role of transporters), metabolism, and efflux, could be 310 
developed to help modellers identify which processes may need to be included for a specific chemical / purpose. 311 
 312 
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Membrane transporters influence the ADME processes of various endogenous and exogenous compounds 313 
(Klaassen and Aleksunes, 2010; SOLVO, 2017). In recent decades, the pharmaceutical field has placed 314 
considerable effort into the study of transporters affecting drug disposition, therapeutic efficacy, and adverse 315 
outcomes, but little is known in regards to transporter effects on environmental chemicals (Clerbaux et al., 316 
2018). Transporters can play a significant role in chemical distribution. As such, integration of membrane 317 
transporter-based experimental data during parameterization of several types of computational models (e.g., 318 
QSAR, pharmacophore, and PBK models), through use of platforms like  SimCyp, PKSim, or GastroPlus,  will 319 
enable better understanding of chemical/drug disposition (Clerbaux et al., 2018).  320 
 321 
Protein binding in plasma influences the partitioning of endogenous and exogenous compounds from the blood 322 
into the tissues. The plasma protein binding property is, among other things, related to lipophilicity, as binding 323 
becomes greater with more lipophilic chemicals, thus sequestering such chemicals in blood and limiting the 324 
systemic availability and distribution of unbound fraction of the chemical. A common and widely used method 325 
for estimating plasma protein binding in vitro is the rapid equilibrium method, which involves measurement of 326 
chemical transport across a dialysis membrane with a high surface area-to-volume ration within a Teflon-lined 327 
plate well (Waters et al., 2008).   328 
 329 
Metabolism is an important feature to consider in a model, especially when a metabolite is assumed or known 330 
to be the toxic moiety. Both in vitro and in silico methods can be informative in providing predictions for 331 
metabolism and clearance. Kirchmair et al (2015) reviewed software for predicting a range of features associated 332 
with metabolism (e.g. identification of labile moieties, enzyme interactions and metabolite prediction).. The 333 
focus of these in silico tools is mainly the estimation of the qualitative nature of the metabolites (i.e., which 334 
ŵetaďolites aƌe foƌŵed ďased oŶ the paƌeŶt ĐoŵpouŶd͛s ŵoleĐulaƌ stƌuĐtuƌeͿ aŶd seldoŵ alloǁs for estimation 335 
of rate constants. A common criticism of software for predicting metabolites is the tendency for over-prediction: 336 
theoretically possible metabolites are not differentiated from those that occur experimentally. Some software 337 
platforms have attempted to address this issue through inclusion of filtering rules. For example, in order to 338 
reduce over-prediction within the Meteor Nexus software (Lhasa Ltd, Leeds), Marchant et al (2017) describe a 339 
process whereby k-nearest neighbor analysis is combined with expert knowledge of biotransformation to reduce 340 
the over-prediction of metabolites. Such in silico models do not predict efflux of metabolites.  341 
 342 
In vitro data for metabolism may be generated using tissue slices, organ (e.g., liver) homogenates, cell lines, 343 
spheroids, or (sub)cellular fractions (such as microsomes, baculosomes, S9, and cytosol1), where metabolism is 344 
measured as loss of the parent compound or production of metabolite(s). It should be noted that if metabolism 345 
occurs very slowly, it may not be detected in a short-term in vitro assay. If a chemical is known to be 346 
predominantly excreted unchanged in urine, then metabolism is less relevant to the model. However, if 347 
metabolism of a parent compound is thought to be metabolized to undergo biliary excretion or to be excreted 348 
via the bile, then a model including such elimination pathways is necessary, first by determining which pathways 349 
of elimination are most relevant to the target chemical. In silico and in vitro models have also been developed 350 
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for predicting different processes involved in elimination. These include in silico models for total clearance 351 
(Lombardo et al., 2014) and metabolism (Pirovano et al., 2015) and in vitro models for biliary excretion (Ghibellini 352 
et al., 2006). However, more work is required to develop models for elimination, and the applicability domain 353 
for existing models should be carefully considered before application to a wider range of chemicals. A current 354 
limitation is that there are no (OECD) guideline(s) addressing in vitro methods to determine kinetic parameters, 355 
except for the guideline on Skin Absorption (OECD TG 428). In the absence of standardised methods for 356 
generating in vitro parameters to calibrate PBK models, it is important that in vitro metabolism data or data 357 
regarding transporters are produced according to the new OECD good in vitro method practice (GIVIMP)3. The 358 
GIVIMP document is meant to serve as technical guidance on generating and applying quality data through good 359 
scientific and quality practices, to support the regulatory human safety assessment of chemicals using in vitro 360 
methods. 361 
 362 
Bessems et al. (2014) provides a general overview of the currently available in vitro and in silico methods for 363 
characterizing human ADME and the gaps and challenges faced.  Mostrag-Szlichtyng et al (2010) provide an 364 
extensive review specifically of in silico tools (i.e., QSAR models and software) for prediction of ADME properties 365 
that are relevant to PBK model building. More recently, Patel et al (2018) have collated and assessed the quality 366 
of over 80 models for 31 absorption-, distribution-, and excretion-related endpoints (Patel et al., 2018).  367 
 368 
Finally, toxicodynamic data derived from in vitro toxicity tests are typically based on nominal concentrations of 369 
the substances, which may contain significant errors due to the loss of biological, physical,  and toxicological 370 
chemical processes in such tests. An in vitro biokinetic study plays a significant role in translating a nominal 371 
concentration used in in vitro systems to the actual level of cell exposure producing the effect. Several 372 
methodologies can be applied to address such a relationship, such as in vitro fate and transport mass balance 373 
models recently developed by several research teams (Kramer 2010a, 2010b; Armitage et al., 2014; Fischer et 374 
al., 2017; Zaldivar Comenges et al., 2017).  375 
 376 
2. Availability of modelling platforms 377 
Currently, several open source modelling platforms, such as IndusChemFAte (Cefic LRI, http://cefic-378 
lri.org/toolbox/induschemfate/), High-Throughput Toxicokinetics (httk)-r package (Wambaugh et al., 2018, 379 
https://cran.r-project.org/web/packages/httk/index.html), MEGEN-RVis (Loizou et al, 2011; 380 
https://megen.useconnect.co.uk/), PLETHEM (http://www.scitovation.com/plethem.html), MERLIN-EXPO 381 
(Ciffroy et al., 2016b; Suciu et al., 2016; https://merlin-expo.eu/), and PK-Sim (www.systems-biology.com), and 382 
license-based platforms such as GastroPlus (www.simulations-plus.com) and SimCyp 383 
(https://www.certara.com), are available to individuals possessing varying degrees of expertise in PBK  384 
modeling.  These platforms provide different computational tools that allow non-programmers to develop and 385 
run model simulations with varying options to gain a better understanding of model behavior, which is essential 386 
                                                          
3 http://www.oecd.org/env/ehs/testing/OECD_Draft_GIVIMP_in_Human_Safety_Assessment.pdf 
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for interpretation of model output. The PBK models run from these platforms can be parameterised using in 387 
vitro or in silico data. However, programmers or users with modeling skills can also use R, MATLAB, and Berkeley 388 
Madonna software to develop customised PBK models, and to support the generation of innovative modeling 389 
components, which might otherwise not be generated through use of the more-structured commercial 390 
platforms. 391 
 392 
A concern for the use of open source modelling platforms, as compared to use of their proprietary counterparts, 393 
is the lack of sustainable resources and funding that are needed for further development and maintenance of 394 
those platforms. While most of these platforms are initiated by a research grant, upon completion of the project, 395 
the developers are often unable to find other funding sources to maintain it. In order for a modelling platform 396 
to ƌeŵaiŶ sustaiŶaďle, it is esseŶtial to ŵaiŶtaiŶ aĐĐess to the ŵodel͛s eƋuatioŶs, so that these ĐaŶ ďe easilǇ 397 
coded later. Sustainability also depends on the ability of model updates to be communicated to end-users. 398 
Establishment of an open source library as a repository for all available model information, including a peer 399 
review process, is strongly recommended.  400 
 401 
 402 
3.  Integrating NG-PBK modelling with toxicodynamic endpoints  403 
There is high value in the use of PBK models to predict internal target tissue doses for risk assessment 404 
applications, based on the assumption that a similar tissue response arises from an equivalent target tissue dose, 405 
rather than the external dose, across different exposure conditions. In addition, toxicodynamic processes that 406 
that are interpreted in a high-throughput context from in vitro dose–response data can be integrated with PBK 407 
models, to link external exposure concentrations to target tissue doses to adverse endpoints. Such integration 408 
allows for support of several risk assessment extrapolations, such as QIVIVE and reverse dosimetry approaches. 409 
Examples of PBK/TD models are reported in table 3 of Punt et al., 2011. However, the application of PBK/TD 410 
models in risk assessment requires proper evaluation of model purpose, model assumptions and structure, 411 
mathematical representation, parameter estimation, computer implementation, and predictive capacity.  412 
 The topic of model evaluation will be captured in the next chapter.   413 
 414 
Salient Features: Model evaluation- assessing the validity of PBK models that rely only upon non-animal data 415 
A ƋuestioŶ that ofteŶ aƌises is ͞How can we trust a PBK model prediction if there are no in vivo data to evaluate 416 
the simulation; how can the model gain credibility then?”  417 
The following approaches could be applied and are described in further detail below: 1) read-across; 2) micro-418 
scale systems; 3) pragmatic conservative scenario approach; 4) ͞credibility matrix͟; 5) the reliability of dose 419 
metric predictions provided with uncertainty and sensitivity analyses (WHO 2010); and 6) population 420 
characteristics and virtual population libraries. 421 
 422 
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1. Read-across 423 
For those cases in which in vivo data exist for one chemical, a read-across approach4 may be applied to 424 
parameterize models for other chemicals (Schultz et al., 2015).  For example, if a valid PBK model exists for 425 
chemical A (source chemical), and chemical B (target chemical) lacks any in vivo data and has been shown to be 426 
similar in structure to chemical A, then the same parameterised PBK model structure/code and in vivo data for 427 
chemical A can be used for chemical B. This read-across approach has been demonstrated by case studies 428 
applying the PBK Knowledgebase developed by Lu et al. (2016). Alternatively, if parameterisation of the PBK 429 
model using available in vitro or in silico data for chemical B is possible, predictions can be compared to output 430 
from the model for chemical A based on in vivo data, in order to evaluate the PBK model for chemical B. When 431 
using such a model based on similarity between different chemicals, the influence of chemical-specific 432 
properties mediating ADME behaviour (e.g., log P, specific functional groups) should be carefully considered.  433 
 434 
2. Micro-scale systems 435 
Microscale systems, such as human-on-a-chip technology, could potentially be applied to measure and predict 436 
kinetics and whole body response to substances (Sung et al., 2014), thus aiding in evaluation and increased 437 
confidence in NG-PBK models. However, the limitations of these novel microscale systems should be carefully 438 
considered. For example, flow rates from model systems are often not scaled down in a similar manner as tissue 439 
volumes, thus rendering interpretation of the data difficult for PBK model applications. 440 
 441 
3. Pragmatic conservative scenario approach 442 
When in vivo data are lacking for model evaluation, a pragmatic conservative scenario could be followed in order 443 
to derive the most conservative estimate for risk assessment. For NG-PBK modeling, such an approach needs to 444 
be designed in such a way that the structure and input of the model is likely to lead to an overestimation of the 445 
internal concentration. This can be achieved by including uncertainty factors in the input parameters of the 446 
model. A worst-case estimate for absorption can for example be set to 100%. Other input parameters, such as 447 
metabolic clearance can be set to a value that is a certain extent lower than that measured for in vitro rates. To 448 
define the conservative boundaries around each input parameter, the uncertainties of each in vitro or in silico 449 
input method need to be identified.   450 
 451 
4. Credibility matrix  452 
There is a need to develop a framework for supporting the credibility of PBK models in support of risk assessment 453 
applications. As a first requirement for credibility, PBK models should be biologically plausible. Often, modellers 454 
or mathematicians exclude a number of biologically-relevant processes because these processes are considered 455 
to have no bearing on the model results and because models should be kept as simple as possible  created 456 
                                                          
4 Quotation: “The underlining philosophy of read-across is that substances which are similar in chemical 
structure will have similar properties and thereby, have similar toxicokinetics and toxicodynamics. 
Experimental derived toxicological proprieties from one substance, often referred to as source chemical, 
can be read across to fill the data gap for a second substance, the target chemical, which has a similar 
molecular structure but is lacking data” (Schultz et al., 2015). 
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following the required purpose/problem formulation. However, such assumptions must always be discussed and 457 
agreed upon with biologists and toxicologists, to prevent the omission of critical biological and toxicological 458 
steps or key events. Good documentation of model assumptions is critical for modelers to demonstrate the 459 
validity of their models to reviewers and users, and visualization is a key feature when dealing with 460 
communication of these models. The recent EFSA uncertainty guidance document provides a reporting table for 461 
listing and evaluating model uncertainties (EFSA 2018).  462 
 463 
From the 2016 EURL ECVAM workshop, the folloǁiŶg gƌaphiĐal ƌepƌeseŶtatioŶ aŶd appliĐatioŶ of the ͞ĐƌediďilitǇ 464 
ŵatƌiǆ ďǇ PatteƌsoŶ & WhelaŶ͟ has been proposed. The matrix (Figure 4) allows for locating a specific model 465 
type based on the information available, i.e whether a model is principled and testable, as well as knowledge of 466 
the biology and the availability of data, which should aid in systematically establishing  model credibility via a 467 
process of social epistemology (Patterson & Whelan, 2017). If a model falls in the bottom left region (testable 468 
and with full knowledge), confidence in  the model is likely high. However, if a model falls in the top right region 469 
of the matrix (not testable and without any knowledge of the system biology), confidence in the model is likely 470 
low due to the uncertainties associated with it. In other words, regulators are unlikely to trust model types found 471 
in the top right region of the matrix when making decisions. The question is, to what degree a PBK model would 472 
need to be placed towards the bottom left corner to attain sufficient credibility for regulators. In some sense, 473 
testable models do not really predict, but provide an estimate to compare against available data in a 474 
retrospective fashion. 475 
 476 
The proposed framework should lay out the requirements for validating models with different degrees of 477 
knowledge and testability (e.g., quantitative validation), which could aid in quantifying the uncertainty currently 478 
existing with animal models, and which can help regulators assess whether models developed through in vitro 479 
and in silico methodologies can be equally reliable, or even more so, compared to current risk assessment 480 
approaches.  Biological systems, by nature, are complex networks operating under simple rules that can be 481 
described by non-linear dynamic processes, and which exhibit non-trivial emergent and self-organizing behavior. 482 
As a result, a measured value might represent a particular, and perhaps unknown, state of a system, which 483 
makes its use, as a comparator for a predicted value, challenging.  To handle such issues, approaches that 484 
operate on experience-based validation are required. Ideally, these, approaches would capture the diversity of 485 
experiences to establish generic digital twins, which are couplings of validated models with their real-world 486 
datasets (see Patterson et al., 2016).  487 
 488 
There is disagreement amongst modellers as to the meaning of the terms model evaluation, verification, and 489 
validation; for instance, EMA has shifted to use of the word ͞qualification͟. Regardless of which term is more 490 
appropriate, the analytical purpose is to ensure that the model is appropriate for the task at hand, and that its 491 
predictions are a reasonable representation of reality. Once confirming that the model is a reasonable 492 
representation of reality for the intended purpose, seǀeƌal aŶalǇses ŵaǇ ďe used to ͞ ǀalidate͟ a ŵodel, iŶĐludiŶg 493 
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sensitivity analysis, robustness analysis5, assumption justification, model argumentation, structured calibration, 494 
predictive performance, proper scoring rules, and relation to ƌealitǇ. To ͞ ǀeƌifǇ͟ a ŵodel, the ŵodel sĐope should 495 
be revisited and the model equations and code reviewed. The following key elements were suggested by the 496 
2016 EURL ECVAM workshop participants to achieve model credibility (Paini et al., 2017a): 497  Understand the model; 498 
 Understand the data underpinning the model; 499 
 State clearly the assumptions and hypothesis encoded; 500  Consider the gap between the model and reality, based on available observations.  501 
This last item can be a description of what is lacking in the model. The outcomes of sensitivity analyses can be 502 
used to explain some model deficits. One possible approach, as opposed to the statement in the introduction 503 
regarding developing the simplest model, would be to start with a more complex model and then remove 504 
parameters to which the predictions are not sensitive. The potential problem with this approach is that when 505 
there are many parameters with large uncertainties, they may introduce a great deal of variation into the 506 
uncertainty analysis. 507 
   508 
5. Reliability of dose metric predictions (model testing, uncertainty, and sensitivity)  509 
In 2010, the World Health Organization (WHO) reported the level of confidence needed to gain credibility in a 510 
PBK model intended for risk assessment (WHO, 2010). The degree of ĐoŶfideŶĐe iŶ a PBK ŵodel͛s pƌediĐtioŶs 511 
depends upon how well the model has been tested against real data and whether adequate sensitivity and 512 
uncertainty analyses have been conducted, in order to support the reliability of predictions (WHO, 2010). In the 513 
case of NG-PBK models, the lack of ͞ƌeal data͟ (e.g in vivo human data) that are required to evaluate model 514 
predictions for the purpose of validation render such validation nearly impossible. However, reporting of 515 
adequate sensitivity and uncertainty is certainly relevant and encouraged. Tables providing guidance in 516 
reporting results of uncertainty and sensitivity analyses have been provided in the WHO 2010 article, as a tool 517 
to better document the evaluation of model predictions (from WHO 2010; Meek et al. 2013). There are several 518 
areas that are considered to present current challenges in accepting model-informed drug development, which 519 
can also provide insight into necessary acceptance criteria for PBK model-based drug development. Among 520 
those criteria, most noteworthy is that the adequacy of submitted PBK models is to be based on their intended 521 
purposes at different stages of drug development (Paini et al., 2017a). That is, determination of whether a model 522 
is fit-for-purpose and the need to identify and transparently communicate the knowledge gaps. EMA and US 523 
FDA published a draft document in 2016 as guidance on the qualification and reporting of physiologically based 524 
pharmacokinetic (PBPK) modelling and simulations (EMA, 2016; US FDA 2018). The aim of this guideline is to 525 
describe the expected content that should be included in PBK modelling and simulation reports during regulatory 526 
submission, including applications for authorization of medicinal products, pediatric investigation plans, and 527 
                                                          
5 Quotation from Saltelli et al 2000 Sensitivity Analysis – What is Sensitivity Analysis? “For a software engineer, 
SA could be related to the robustness and reliability of the software with respect to different assumptions “ 
… “For a statistician, involved in statistical modelling, SA is mostly known and practice under the heading 
of “robustness analysis” (Saltelli, 2000). 
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clinical trial applications. This also includes the documentation needed to support the qualification of a PBK 528 
platform for an intended use, such as results of sensitivity and uncertainty analyses. 529 
6. Population characteristics and virtual population libraries  530 
This chapter reports information on population characteristics as virtual population libraries for the in silico 531 
medicine field. However we believe that this information could be also relevant for the chemical risk assessment. 532 
Efforts undertaken to better capture the heterogeneity in the human species can certainly be applied to 533 
environmental chemical risks, as different population cohorts may be more at risk to specific chemical exposures 534 
than are other cohorts. Important aspects of human heterogeneity include inter-individual variations in lifestyle, 535 
health status (immunosuppressed, disease patient) genetic polymorphism (gene expression), physiology (uptake 536 
rate), biochemistry and molecular biology (Mclanahan et al., 2012), all with respect to age. These factors will 537 
interact and influence the chemical ADME and biokinetic behaviors and toxicodynamics within the body. 538 
Parameters in a PBK model have a direct biological correspondence, providing a useful framework for 539 
determining the impact of observed variations in physiological and biochemical factors on the population 540 
variability in the achieved target of a particular chemical (Clewell and Andersen, 1996; Price et al., 2003; 541 
Mclanahan et al., 2012). In addition, integration of genetic information from –omics studies will enhance 542 
predictions for precise and personalized medicine.  Applications for predicting the kinetics of substances within 543 
specific populations, such as in the field of pediatrics, have been increasing in their  development and use (Leong 544 
et al., 2012). In the pharmaceutical field, population-specific PBK models can simulate untestable clinical 545 
outcomes, allowing for evaluating the effects of intrinsic (e.g., organ dysfunction, age, genetics, etc.) and 546 
extrinsic (e.g., drug-drug interactions) factors, alone or in combination, on drug target concentrations.  547 
  548 
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Next steps and future perspectives 549 
With an increasing demand for application of alternative methods within the risk assessment framework, the 550 
need for the development of higher throughput NG-PBK models has also increased. A guidance document for 551 
GMP for PBK modelling could also be extended to other types of in silico biokinetic models, such as in vitro mass 552 
balance models (Armitage et al., 2014; Zaldivar Comenges et al., 2017). Existing guidance documents (WHO, 553 
2010 and EPA, 2006), and those documents of EFSA (2014), and European Committee for Standardization (CEN, 554 
2015), that are less PBK-specific, require updating with respect to the current trends, due to the continuous 555 
evolution in science and risk assessment. The recent United States Food and Drug Administration (US FDA, 2018) 556 
and European Medicine Agency (EMA, 2016) guidelines are the first that open up the possibility to submit non-557 
animal PBK model results for drug dossier submission and provide excellent examples that other agencies could 558 
follow. At the same time, the OECD is working on a guidance document for the characterization, validation, and 559 
reporting of physiologically based models for regulatory applications that should be ready in 2019, and which 560 
attempts to set principles for NG-PBK model validation. 561 
However, the challenge remains in making appropriate use of in vitro data and/or in silico predictions when 1) 562 
building these models; 2) interpreting model outputs and integrating the outputs with other sources of 563 
information for risk assessment purposes; and 3) attempting to gain model credibility by underlining all 564 
uncertainties and assumptions when in vivo human data are unavailable for proper model evaluation. The 565 
uncertainty and variability associated with PBK models, and the proposed GMP (Loizou et al., 2008), should be 566 
further developed and should include guidance for PBK models built using in vitro and in silico methodologies to 567 
estimate ADME properties. The use of a matrix in the new risk assessment paradigm, to underline and quantify 568 
the uncertainty associated with NG-PBK models, compared to models based on in vivo animal data, would be 569 
desirable.  570 
Several standardised decision trees could be developed to guide modellers in their construction of a PBK model 571 
in the absence of in vivo data for calibration, and to guide risk assessors in application and interpretation of PBK 572 
models. For instance, PBK-predicted internal dose metrics vs. in vitro PoD from toxicity testing could be taken 573 
into account, along with in vitro results linking to in vivo adverse outcomes for a tiered assessment, perhaps 574 
through application of the traditional and internal threshold of toxicological concern (TTC) approach (Kroes et 575 
al., 2007; Worth et al., 2012). With the need for several international working groups to further develop such 576 
documentation, communication is required among these groups to ensure compatibility of in vitro kinetic and 577 
dynamic methods with PBK models, in addition to communication with regulators to fit the total risk-assessment 578 
framework. It should be noted that for such communication to be achieved, funding would be necessary. 579 
There remains a need to create a community to address issues with human ADME/TK and NG-PBK models, such 580 
as the development of criteria for model construction and model evaluation. A group of scientists across the 581 
academic, industrial, and governmental landscapes should be available and willing to establish a peer review 582 
system for PBK models. Criteria should exist to select those individuals that will review the models, and 583 
templates and check lists should be provided to assist in the review process. A public repository is needed for 584 
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PBK models that have been built and/or peer reviewed, and once this repository is developed, relevant 585 
documentation can be introduced from an independent peer review to support model credibility. Such a 586 
repository is in line with the work reported in Lu et al., (2016) and will allow for the curation of more case studies 587 
and the creation of libraries of ad hoc PBK models that could be used for training purposes. Additionally, this 588 
repository will facilitate risk assessment approaches applying PBK models and IVIVE, and communicate to 589 
decision makers more efficiently the current state of science regarding the use of animal-free models in 590 
regulatory applications. Perspectives from the various industrial stakeholders (e.g. pharmaceutical, food safety, 591 
agricultural, and personal care product industries) also need to be communicated, to provide greater insight of 592 
current practice and understanding of future needs of these sectors, to enable promotion of best practices.  593 
Application of NG-PBK models, in the context of exposure in specific population of patients, would be extremely 594 
valuable in the generation of virtual population/patient libraries. These libraries would enable clinical trials to 595 
entail populations with a greater Ŷuŵďeƌ of ͞ǀiƌtual͟ iŶdiǀiduals, ǁhiĐh ŵight Ŷot otheƌǁise ďe possiďle to 596 
conduct with a limited number of real persons/patients. Additionally, these libraries would introduce 597 
populations more rarely encountered, such as those possessing enzyme polymorphisms that exert a greater 598 
influence on drug-drug interactions or those with rare genetic diseases or health abnormalities. Such libraries 599 
would also prove useful in chemical risk assessment when evaluating interindividual variability in relation to 600 
chemical exposures and toxicological outcomes.    601 
Finally, it is recommended that a means for training new modellers and risk assessors be established . Such 602 
training, which can be provided with specific courses or as a continuous education course within scientific 603 
conferences, will focus on PBK model development, evaluation, and application. Though several challenges still 604 
remain, the suggestions and steps presented in this work provide a path towards gaining acceptance of NG-PBK 605 
models in regulatory practices.  606 
In summary, to facilitate the development and use of NG-PBK models, which do not rely on animal in vivo data, 607 
and their acceptance in the regulatory domain, the following are recommended:  608 
i) development of more transparent, accessible, and user-friendly software platforms that facilitate 609 
development and application of PBK models by a community of users, and which allow specific populations to 610 
be modelled or population variability to be evaluated; 611 
ii) development of resources to inform new developments in in silico and in vitro approaches that may be used 612 
to provide data for model development; 613 
iii) development and refinement of existing web applications and PBK model platforms that have the ability to 614 
conduct QIVIVE and reverse dosimetry in an automated manner;  615 
iv) knowledge sharing initiatives that allow members of the regulatory community, such as risk assessors and 616 
risk managers, to become familiar with relevant PBK model information, while model developers gain a better 617 
understanding of regulatory needs; 618 
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v) GMPs and harmonised guidelines for reporting the steps taken during model development, evaluation, and 619 
application, with respect to NG- PBK models. This would include the use of a clear and common terminologies.  620 
 621 
  622 
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Figure Legend  842 
Figure 1. (a) Schematic representation of a physiologically based kinetic (PBK) model, (b) with an example of a typical PBK 843 
model-output (time-dependent chemical concentration in blood). 844 
Figure 2. A. Number of papers published per year within the last 60 years. The search was conducted using the online 845 
repository PubMed on the 7th of MaƌĐh ϮϬϭϴ, ǁith keǇ ǁoƌds stƌiŶg iŶĐludiŶg ͞PBPK O‘ PBBK O‘ PBTK O‘ PBK͟. B. The 846 
Ŷuŵďeƌ of papeƌs ;figuƌe Ϯ AͿ puďlished ǁith keǇ ǁoƌds stƌiŶg iŶĐludiŶg ͞PBPK O‘ PBBK O‘ PBTK O‘ PBK͟ ǁeƌe Ŷoƌŵalized 847 
to the following terms: Toxicology;  Pharmacology; Chemical Safety OR Risk assessment; Forensic Sciences and Veterinary. 848 
Figure 3. An example of a schematic decision tree to decide what tier of PBK model to apply when encountering 849 
data-poor or data-rich chemicals during model parameterization and based on problem formulation.  850 
Figure 4. Credibility matrix showing comparative loci for a model based on traditional in vivo data-based approaches and for 851 
a model based on an alternative approach (i.e., in vitro, in silico methods and/or micro-scale systems). The rationale for the 852 
locations of the model types, indicated by stars and letters, are given in the side-bar legend. For example, in silico models 853 
plaĐed at the top ƌight, ŵight ĐoŶsist of a siŵple ŵodel ͚a͛ ďased oŶ a liŵited set of data, foƌ instance in a QSAR. This leads 854 
to a ŵoƌe sophistiĐated, ďut still heuƌistiĐ, ŵodel ͚ď͛ ďased oŶ the uŶdeƌstaŶdiŶg gaiŶed fƌoŵ ŵodel ͚a͛. The pƌediĐtioŶs 855 
fƌoŵ ŵodels ͚a͛ aŶd ͚ď͛ aƌe used to desigŶ in vitro tests that eŶaďle the deǀelopŵeŶt of ŵodel ͚Đ͛, ǁhich can be validated 856 
using the rational-empirical approach, thus enhancing its credibility. Finally, this leads to the development of clinical studies 857 
aŶd ŵodel ͚d͛, suppoƌted ďǇ its pƌedeĐessoƌs aŶd ƋuaŶtitatiǀelǇ ǀalidated oƌ ĐoŶfiƌŵed usiŶg ĐliŶiĐal data. This places model 858 
͚d͛ iŶ the ďottoŵ left ĐoƌŶeƌ, as a ŵodel ǁhose pƌediĐtioŶs stakeholdeƌs, iŶĐludiŶg ƌegulatoƌs, pƌaĐtitioŶeƌs, aŶd patieŶts, 859 
will likely use to make decisions (adapted from Paini et al., 2017a, proposed by Patterson and Whelan 2017). 860 
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